1Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl-2 and regulation of apoptosis. Leukemia, 2001,15: 515-522, 869-746.
2Nishikura K, ar-Rushdi A, Erikson J, et al. Differential expression of the normal and of the translocated human c-myc oncogene in B cells. Proc Natl Acad Sci U S A, 1983, 80: 4822-4826.
3Yunis JJ, Frizzera G, Oken MM, et al. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med, 1987,316:79-84.
4Cotter FE. Antisense therapy for malignancy. J Clin Oncol, 2000,18:338-348.
5Ueno H, Kondo E, Yamamoto-Honda R,et al. Association of insulin receptor substrate proteins with Bcl-2 and their effects on its phosphorylation and antiapoptoptic function. Mol Biol Cell,2000,11:735-746.
7Schmitt CA,Rosenthal CT,Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med, 2000,6:1029-1035.
8Tzung S P,Kim KM,Basanez G, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol, 2001, 3:183-191.
9Cotter FE,Corbo M,Raynand F,et al. Bcl-2antisense therapy in lymphoma: In vitro and in vivo mechanisms,efficacy,pharmacokinetics and toxicity studies. Ann Oncol, 1996,7:32-40.
10Yamamoto S,Yamamoto T,Kataoka T,et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. Immnuol,1992,148:4072-4076.
